Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Table 3

Summary of selected ongoing clinical trials of PD-1/PD-L1 ICIs in NHL.

Disease, phase	Phase	Intervention	ClinicalTrials.gov NCT reference
Aggressive B-cell lymphomas
DLBCL, r/r	Ib	Pembrolizumab in combination with tisagenlecleucel	NCT03630159
DLBCL and PMBCL, r/r	II	Pembrolizumab in combination with copanlisib	NCT03484819
DLBCL with PD-L1 genetic alterations, r/r	II	Pembrolizumab monotherapy	NCT03990961
Aggressive B-cell lymphoma, untreated	II	Nivolumab in combination with DA-EPOCH-R	NCT03749018
HGBCL with MYC, BCL2, and/or BCL6 rearrangement, untreated	II	Nivolumab as consolidation after DA-EPOCH-R	NCT03620578
DLBCL, untreated	II	Avelumab as induction and maintenance with R-CHOP	NCT03244176
EBV-positive NHL and EBV-positive PTLD, untreated or relapsed	II	Nivolumab monotherapy	NCT03258567
DLBCL, r/r	Ib	Magrolimab (Hu5F9-G4) in combination with rituximab or R-GemOx	NCT02953509
Aggressive B-cell lymphomas, extranodal
PCNSL or PTL, r/r	II	Nivolumab monotherapy	NCT02857426
CNS lymphoma, r/r	II	Nivolumab in combination with ibrutinib	NCT03770416
PCNSL, relapse after prior 1^st line HiDMTX	II	Pembrolizumab monotherapy	NCT02779101
PCNSL, r/r	I	Nivolumab in combination with pomalidomide	NCT03798314
Transformed indolent B-cell lymphoproliferative diseases
RT-DLBCL or transformed FL	I	Nivolumab in combination with copanlisib	NCT03884998
RT-DLBCL	II	Atezolizumab in combination with obinutuzumab+venetoclax	NCT04082897
Peripheral T-cell lymphomas
NKTL, untreated or r/r	I	Nivolumab in combination with L-asparaginase/GDP	NCT04230330
NKTCL, untreated	II	Sintilimab in combination with Peg-asparaginase/GemOx	NCT04127227
MF and SS, r/r		Pembrolizumab combined with radiotherapy	NCT03385226
ALCL, r/r	II	Nivolumab as treatment or consolidative immunotherapy	NCT03703050
Cutaneous TCL, r/r	II	Atezolizumab monotherapy	NCT03357224
PTCL or cutaneous TCL, r/r	I/II	Durvalumab±lenalidomide	NCT03011814

Abbreviations: ALCL: anaplastic large cell lymphoma; CNS: central nervous system; DLBCL: diffuse large B-cell lymphoma; EBV: Epstein-Bar virus; FL: follicular lymphoma; HGBCL: high-grade B-cell lymphoma; HiDMTX: high-dose methotrexate; LPD: lymphoproliferative disorders; NHL: non-Hodgkin lymphoma; NKTL: natural killer T-cell lymphoma; PCNSL: primary central nervous system lymphoma; PD-1: programmed cell-death protein 1; PD-L1: programmed cell-death 1 ligand; PMBCL: primary mediastinal B-cell lymphoma; PTCL: peripheral T-cell lymphoma; PTL: primary testicular lymphoma; RT-DLBCL: Richter’s transformation of CLL to DLBCL; TCL: T-cell lymphoma.